Veracyte,
Inc. (NASDAQ: VCYT) today announced that data from five studies
validating the performance of the next-generation Afirma®
Genomic Sequencing Classifier (GSC) in thyroid cancer diagnosis will be
presented at the 87th Annual Meeting of the American Thyroid
Association (ATA) being held October 18-22 in Victoria, BC, Canada. Two
oral and three poster presentations will demonstrate the Afirma GSC’s
ability to further reduce unnecessary surgeries in thyroid cancer
diagnosis while providing physicians information to enable more
appropriate treatment when suspicious nodules are identified.

"We believe the results of these studies highlight the Afirma GSC's
unique ability to provide physicians with answers, including answers to
the most challenging biological questions, as they evaluate patients for
thyroid cancer," said Bonnie Anderson, Veracyte's chairman and chief
executive officer. "These data reinforce our commitment to develop the
extensive clinical evidence required to gain both physicians' and
patients' confidence in using our genomic tests to inform important
patient-care decisions."

Data from two studies evaluating the Afirma GSC's performance in two of
the most challenging thyroid biologies will be shared as oral
presentations at the ATA meeting:

The Afirma Genomic Sequencing Classifier is the next-generation version
of the Afirma Gene Expression Classifier, and is used to identify
patients with benign thyroid nodules among those with indeterminate
cytopathology results in order to preserve the thyroid. Each year in the
United States, more than 525,000 fine needle aspiration biopsies are
performed to assess patients with potentially cancerous thyroid nodules.
Up to 30 percent of the results are indeterminate (not clearly benign or
malignant) and physicians have traditionally recommended thyroid surgery
for a more definitive diagnosis. Following surgery, however, 70 to 80
percent of patients' nodules are diagnosed as benign, meaning the
surgery was unnecessary. Such surgery is invasive, costly and often
leads to the need for lifelong daily thyroid hormone replacement drugs.

About Veracyte

Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is
providing trustworthy and actionable answers that fundamentally improve
patient care when current diagnostic tests are uncertain. The company's
products uniquely combine genomic technology, clinical science and
machine learning to provide answers that give physicians and patients a
clear path forward without risky, costly surgery that is often
unnecessary. Since its founding in 2008, Veracyte has commercialized
three genomic tests, which are transforming the diagnosis of thyroid
cancer, lung cancer and idiopathic pulmonary fibrosis and collectively
target a $2 billion market opportunity. Veracyte is based in South San
Francisco, California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "expect," "believe," "should," "may,"
"will" and similar references to future periods. Examples of
forward-looking statements include, among others, our belief that our
Afirma GSC's ability to further reduce unnecessary surgeries in thyroid
cancer diagnosis while providing physicians information to enable more
appropriate treatment when suspicious nodules are identified, our
beliefs with respect to the results of the studies, including Afirma
GSC's ability to provide answers to the most challenging biological
questions in evaluating patients, our commitment to developing extensive
clinical evidence required to generate confidence in our products, and
the applicability of clinical results to actual outcomes.
Forward-looking statements are neither historical facts nor assurances
of future performance. Instead, they are based only on our current
beliefs, expectations and assumptions regarding the future of our
business, future plans and strategies, anticipated events and trends,
the economy and other future conditions. Forward-looking statements
involve risks and uncertainties, which could cause actual results to
differ materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties include,
but are not limited to: the applicability of clinical results to actual
outcomes; laws and regulations applicable to our business, including
potential regulation by the Food and Drug Administration or other
regulatory bodies; the ability of our products to change treatment
decisions and reduce unnecessary surgeries; the occurrence and outcomes
of clinical studies; the timing and publication of clinical study
results; and other risks set forth in the company's filings with
the Securities and Exchange Commission, including the risks set forth in
the company's Quarterly Report on Form 10-Q for the quarter ended June
30, 2017. These forward-looking statements speak only as of the date
hereof and Veracyte specifically disclaims any obligation to update
these forward-looking statements.

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma
logo are trademarks of Veracyte, Inc.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.